Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | PLK1 | P53350 | 2/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341052 | 0.92 | HTR4 (0.44) | IGF1RUTS2RSSTR5KCNH2SLC6A5 | |
| SCHEMBL5159689 | 0.89 | KDR (0.45) | UTS2RDGAT2 | |
| SCHEMBL6580849 | 0.88 | DRD4 (0.53) | ROCK2ROCK1SSTR5KCNH2SSTR1 | |
| Hydrochloric Acid SCHEMBL6787079 | 0.88 | DRD4 (0.52) | ROCK2ROCK1SSTR5KCNH2SSTR1 | |
| SCHEMBL6582454 | 0.86 | EZH2 (0.39) | DGAT2SSTR5KCNH2 | |
| SCHEMBL14341049 | 0.85 | EZH2 (0.41) | DGAT2SSTR5KCNH2SSTR1HRH1 | |
| SCHEMBL220979 | 0.84 | KMT2A (0.51) | — | |
| SCHEMBL14341048 | 0.84 | MAPT (0.35) | DGAT2SSTR5KCNH2 | |
| SCHEMBL14341047 | 0.81 | TSHR (0.34) | ALKUTS2RBRD4PLK1SSTR5 | |
| SCHEMBL6580730 | 0.81 | TSHR (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | claimed |
| EP-1753420-A1 | INDOLE DERIVATIVES USEFUL FOR TREATING RESISTANCE TO ANTITUMOUR AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2007-02-21 | — | — | EP | claimed |
| WO-2005105078-A1 | INDOLE DERIVATIVES USEFUL FOR TREATING RESISTANCE TO ANTITUMOUR AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | claimed |
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | disclosed |
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | NIKEM RESE S.R.L. (IT) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299084-A1 | Indole Derivatives Useful for Treating Resistance to Antitumor Agents | IDO1, IDO2, INMT | IGF1R 195/4885ALK 4333/4885UTS2R 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.